The reason is clear. Diabetes is affecting a large global population, while kidney damage can develop quietly for years. The World Health Organization (WHO) reported that the number of people living with diabetes increased from 200 million in 1990 to 830 million in 2022. Diabetes and kidney disease caused by diabetes were associated with more than 2 million deaths in 2021.
According to Persistence Market Research, the global diabetic nephropathy market is estimated to be valued at US$3.7 billion in 2026 and is predicted to reach US$5.1 billion by 2033, growing at a CAGR of 4.7% during the forecast period. This growth is attributed to the rising prevalence of Type 2 diabetes worldwide, which raises the risk of kidney-related complications.
Silent Kidney Damage is Making Early Testing More Important
Diabetic kidney disease often develops without noticeable symptoms. This creates a major gap between disease development and diagnosis. The U.S. Centers for Disease Control and Prevention (CDC) estimates that about 38% of U.S. adults with diabetes have chronic kidney disease. The rate is even higher among adults with Type 1 diabetes, at about 49%.
This is changing how healthcare providers approach diabetes management. Kidney testing is now becoming part of routine diabetes care rather than something reserved for patients with advanced disease. The World Health Organization (WHO) recommends simple blood and urine testing for kidney disease detection. This supports wide use of routine screening in primary care and diabetes clinics.
Market impact: Early testing expands the addressable market beyond advanced kidney disease. Diagnostic companies, laboratories, and treatment providers are predicted to serve patients at early stages.
Diabetes Drugs Are Taking on a Key Role in Kidney Protection
The treatment conversation is changing. Controlling blood glucose remains important, but kidney protection is becoming a key part of diabetes treatment decisions. For example,
- In January 2025, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and kidney disease progression, as well as cardiovascular death, in certain adults with type 2 diabetes and chronic kidney disease.
- Reuters reported that the decision made semaglutide the first GLP-1 treatment approved in the U.S. for this specific population.
This example shows how companies are extending established diabetes medicines into complications associated with the disease.
Risk Assessment is Moving Beyond Detecting Existing Damage
Treatment alone does not solve the problem if high-risk patients are identified too late. This is encouraging companies to combine disease monitoring with treatment decisions. For instance,
- In September 2025, Renalytix announced a collaboration with Tempus to advance intelligent risk assessment for diabetic kidney disease. The collaboration focused on using data to improve risk assessment and treatment decisions.
This direction creates a broad market opportunity. Diagnostic companies are not only looking at whether kidney damage exists. They are also developing tools that can help identify which patients face a higher risk of progression. For healthcare providers, this is projected to support more targeted follow-up. For pharmaceutical companies, better risk identification can help identify patients who may benefit from treatment earlier.
Diabetic Kidney Care is Becoming More Connected
Diabetic kidney disease is closely linked with high blood pressure and cardiovascular risk. The CDC notes that high blood glucose and high blood pressure can both damage kidney blood vessels over time.
This means the market is moving toward a broad care model. Diabetes treatment, blood pressure management, kidney testing, and cardiovascular risk management constantly need to work together. The result is a more connected market rather than separate treatment categories operating independently.
Emerging Markets Still Face Major Gaps in Diagnosis and Treatment
The global opportunity is not limited to the U.S. or Western Europe. The WHO reports that diabetes prevalence has risen more rapidly in low- and middle-income countries. It also notes that access to essential medicines, testing, healthcare workers, and kidney services remains uneven.
This creates a different type of market opportunity. In developed healthcare systems, companies may compete through advanced risk assessment and newer medicines. In emerging markets, affordability, availability, basic testing, and primary-care access can have a large effect on adoption.
India is a prominent example. WHO India estimates that about 77 million adults in the country have type 2 diabetes, while nearly 25 million have prediabetes. It also identifies diabetes as one of the leading causes of kidney failure in the country. For companies, this means expansion strategies need to reflect local healthcare conditions. Low-cost testing, wide screening networks, and accessible treatment can be as important as advanced products.
Clinical Evidence is Influencing the Next Wave of Kidney Therapies
Regulatory decisions are influencing product development. The FDA approval of Ozempic for kidney-related outcomes demonstrates how evidence from large clinical studies can support additional uses for established medicines. For drug developers, this raises the importance of proving benefits beyond blood glucose control.
Kidney outcomes, cardiovascular outcomes, safety, and long-term disease progression can all influence product positioning. This also matters for retailers and healthcare distributors. Products with broad approved uses may reach more patients, while products requiring specific monitoring may need stronger coordination with healthcare providers.
What Comes Next for Diabetic Nephropathy?
The diabetic nephropathy market is becoming broader than a conventional kidney-treatment segment. Early testing is bringing patients into care sooner. New treatment strategies are connecting diabetes control with kidney protection. Data-driven risk assessment is adding another layer to diagnosis and patient management.
The next phase will likely depend on how effectively these areas connect. The WHO estimates that around 674 million people worldwide live with chronic kidney disease, with most living in low- and middle-income countries.
The opportunity, therefore, is not only about developing another treatment. It is about finding kidney disease earlier, identifying patients at higher risk, expanding access, and linking diagnosis with long-term treatment. Companies that address these gaps are projected to participate across multiple points of the diabetic kidney disease care pathway.
